What should be the primary target of "treat to target" in psoriatic arthritis?

What should be the primary target of "treat to target" in psoriatic arthritis?

<h4>Background</h4> <p>Treat to Target in psoriatic arthritis (PsA) recommendations have stated that the target should be remission or inactive disease. Potential definitions include Very Low Disease Activity (VLDA), PsA Disease Activity Score (PASDAS) near remission, Disease Act...

Descripció completa

Dades bibliogràfiques
Autors principals:	Coates, LC, Lubrano, E, Perrotta, FM, Emery, P, Conaghan, PG, Helliwell, PS
Format:	Journal article
Idioma:	English
Publicat:	Journal of Rheumatology 2018

Ítems similars

What should be the primary target of ‘treat to target’ in PsA?
per: Coates, L, et al.
Publicat: (2018)

Treat-to-target in psoriatic arthritis—cost-effective in the biosimilar era
per: Coates, L, et al.
Publicat: (2022)

Long-term follow-up of patients in the TIght COntrol of inflammation in early Psoriatic Arthritis (TICOPA) trial
per: Coates, L, et al.
Publicat: (2019)

Sustained very low disease activity and remission in psoriatic arthritis patients
per: Lubrano, E, et al.
Publicat: (2019)

Secukinumab for ankylosing spondylitis and psoriatic arthritis
per: Lubrano E, et al.
Publicat: (2016-10-01)

New approved drugs for psoriatic arthritis
per: F.M. Perrotta, et al.
Publicat: (2016-09-01)

Precision medicine in psoriatic arthritis: how should we select targeted therapies?
per: Al-Mossawi, H, et al.
Publicat: (2019)

Sustained Very Low Disease Activity and Remission in Psoriatic Arthritis Patients
per: Ennio Lubrano, et al.
Publicat: (2019-08-01)

How should we define disease and outcomes in axial psoriatic arthritis?
per: Coates, LC
Publicat: (2021)

Difficult to Treat and Refractory to Treatment in Psoriatic Arthritis
per: Ennio Lubrano, et al.
Publicat: (2023-07-01)

THE DIAGNOSIS OF PSORIATIC ARTHRITIS
per: P.S. Helliwell
Publicat: (2011-09-01)

The dynamics of response as measured by multiple composite outcome tools in the TIght COntrol of inflammation in early Psoriatic Arthritis (TICOPA) trial.
per: Coates, L, et al.
Publicat: (2017)

Does treat to target or achieving remission improve radiographic outcome in psa?
per: Coates, L, et al.
Publicat: (2016)

Simulation-based design of pragmatic trials in psoriatic arthritis using propensity scores
per: Weinstein, SM, et al.
Publicat: (2021)

Novel concepts in psoriatic arthritis management: Can we treat to target?
per: Tucker, L, et al.
Publicat: (2018)

Mixed methods study of clinicians’ perspectives on barriers to implementation of treat to target in psoriatic arthritis
per: Dures, E, et al.
Publicat: (2020)

Comparing the visual analogue scale and the numerical rating scale in patient-reported outcomes in psoriatic arthritis
per: Ye, W, et al.
Publicat: (2021)

Time to response for clinical and patient-reported outcomes in patients with psoriatic arthritis treated with tofacitinib, adalimumab, or placebo
per: Gladman, DD, et al.
Publicat: (2022)

The comparative performance of three screening questionnaires for psoriatic arthritis in a primary care surveillance study
per: Helliwell, PS, et al.
Publicat: (2023)

Assessment of patient-physician interactions in psoriatic arthritis: national results of the ASSIST Study
per: Perrotta, FM, et al.
Publicat: (2024)

Measuring physical function in psoriatic arthritis: comparing the Multi-Dimensional Health Assessment Questionnaire to the Health Assessment Questionnaire Disability Index
per: Ye, W, et al.
Publicat: (2021)

Occult axial involvement in patients with psoriatic arthritis mutilans: a case report
per: F.M. Perrotta, et al.
Publicat: (2019-07-01)

Current concepts and unmet needs in psoriatic arthritis
per: Mahmood, F, et al.
Publicat: (2017)

Psoriatic arthritis: prospects for the future
per: Hackett, S, et al.
Publicat: (2022)

Should methotrexate have any place in the treatment of psoriatic arthritis?
per: Ye, W, et al.
Publicat: (2019)

Evaluation and validation of a patient completed psoriatic arthritis flare questionnaire
per: Helliwell, PS, et al.
Publicat: (2021)

Psoriasis, psoriatic arthritis, and rheumatoid arthritis: Is all inflammation the same?
per: Coates, L, et al.
Publicat: (2016)

Measuring outcomes in psoriatic arthritis
per: Ogdie, A, et al.
Publicat: (2020)

Outcome measures in psoriatic arthritis: where next?
per: Hackett, S, et al.
Publicat: (2022)

Sequencing of Biologic and Target Synthetic Disease-Modifying Anti-Rheumatic Drugs in Psoriatic Arthritis: Are we Ready to Redefine the Treatment Strategy? A Perspective
per: Ennio Lubrano, et al.
Publicat: (2022-12-01)

Psoriatic arthritis: lessons from imaging studies and implications for therapy
per: Mathew, A, et al.
Publicat: (2016)

Assessing disease activity in psoriatic arthritis: a literature review
per: Tucker, L, et al.
Publicat: (2018)

Treatment to target in psoriatic arthritis with apremilast: probability of achieving targets and comprehensive control of disease manifestations
per: Mease, PJ, et al.
Publicat: (2020)

Comparing psoriatic arthritis low-field magnetic resonance imaging, ultrasound and clinical outcomes: data from the TICOPA trial
per: Helliwell, P, et al.
Publicat: (2019)

Cost-effectiveness of tight control of inflammation in early psoriatic arthritis: economic analysis of a multicenter randomized controlled trial
per: O'Dwyer, J, et al.
Publicat: (2018)

Remission in psoriatic arthritis—where are we now?
per: Coates, L, et al.
Publicat: (2017)

Identification of psoriatic arthritis in patients with psoriasis
per: Coates, LC, et al.
Publicat: (2023)

GRAPPA 2021 treatment recommendations for psoriatic arthritis
per: Soriano, ER, et al.
Publicat: (2023)

Psoriatic arthritis: imaging techniques
per: E. Lubrano, et al.
Publicat: (2012-06-01)

Validation of new potential targets for remission and low disease activity in psoriatic arthritis in patients treated with golimumab
per: Coates, L, et al.
Publicat: (2018)